The FDA on March 16, 2023, approved TAFINLARĀ® with MEKINISTĀ® for pediatric patients 1 year of age and older with Low-Grade Glioma (LGG) with a BRAF V600E mutation who require systemic therapy. The FDA also approved new oral formulations of both drugs suitable for patients who cannot swallow pills. TAFINLARĀ® and MEKINISTĀ® are products of Novartis.
Other Pages – Bottom Ad
Advertisement
Subscribe
